A.I. Software Board Approves Company Name Change to Pluristem Life Systems PR Newswire -- May 7, 2003 VANCOUVER, British Columbia, May 7 /PRNewswire-FirstCall/ -- A.I. Software, Inc. (OTC Bulletin Board: ASOW) announced today that its Board of Directors has approved changing the name of the company to Pluristem Life Systems, Inc. The company, which recently bought the exclusive rights to stem cell expansion technology that could be pivotal in enabling cord blood transplants in adults, shortly will file documents with the Securities and Exchange Commission requesting the name change. The company will continue to trade under its current ticker symbol until it receives regulatory approval for the new name and a new ticker symbol. "We felt the name Pluristem better reflected our core business and the future development of the scientific and technological advances that are the foundation of what we do," said board spokesperson Meir Segev. "The Board of Directors believes the name Pluristem better defines our goals and mission." The company recently signed an agreement with the Weitzman Institute of Science and Technion -- Israel Institute of Technology to acquire patented technology in its early stages that expands stem cells from umbilical cord blood without differentiation, possibly allowing better results in cord blood transplants in adults. As part of the agreement, A.I. received licensing rights to a stromal cell bioreactor-a unique process and protein that assists in restoring the bone marrow in adults suffering from leukemia, lymphomas, autoimmune disease and other blood-related disorders. Safe Harbor Statement: Statements in this document that are not purely historical are forward- looking statements, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Forward-looking statements in this release include statements regarding: the filing of a change of name with the OTC BB and the Corporation developing stem cell technology that could become a useful and even pivotal product for bone marrow transplants in adults. It is important to note that actual outcomes and the Corporation's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the possibility that the new name is not acceptable by the regulatory authorities, the inability to complete its obligations under the technology license agreement, failure of the technology to be approved for bone marrow transplants, inability to finance the planned development of the technology and unforeseen technical difficulties in developing the stem cell technology, which could among other things, delay product release and impede the planned development of the technology. Further, there may be failure of a sufficient market to develop for the planned products and processes of the Corporation. CONTACT: Angel Streeter, +1-561-750-9800, ext. 21, or AStreeter@transmediagroup.com